CPC A01K 67/027 (2013.01) [A61K 31/198 (2013.01); A61K 38/00 (2013.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 43/00 (2018.01)] | 21 Claims |
1. A method of inhibiting or reducing incorporation of β-N-methylamino-L-alanine (BMAA), 2,4-diaminobutyric acid (2,4-DAB), 2,3-diaminobutyric acid (2,3-DAB), N-(2-aminoethyl)glycine (AEG) or β-N-methyl-alanine (BAMA) into one or more proteins of a mammalian cell in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutical composition consisting essentially of:
(1) an active ingredient selected from the group consisting of L-serine, a salt of L-serine and an L-serine ester; and
(2) at least one pharmaceutically acceptable carrier or excipient;
wherein the pharmaceutical composition includes the active ingredient in an amount of from 10 to 50 grams per day, and
wherein the active ingredient is sufficient to inhibit or reduce incorporation of β-N-methylamino-L-alanine (BMAA), 2,4-diaminobutyric acid (2,4-DAB), 2,3-diaminobutyric acid (2,3-DAB), N-(2-aminoethyl)glycine (AEG) or β-amino-N-methyl-alanine (BAMA), into the one or more proteins of the mammalian cell.
|